BACKGROUND: HIV is a neuropathogenic virus that may result in detrimental neurodevelopmental (ND) outcomes early in life. This is the first study to evaluate the effect of HIV-1 subtype on neurodevelopment of Ugandan preschool children. METHODS:Neurodevelopment of 87 HIV-1 infected and 221 HIV exposed uninfected Ugandan children 1.8-4.9 years of age was assessed using 4 scales of the Mullen Scales of Early Learning (MSEL), 2 scales of the Color Object Association Test (COAT), and 1 score of the Early Childhood Vigilance Test. HIV-1 subtype was defined by phylogenetic analyses. General linear models were used to relate test scores to HIV-1 subtype (A versus D) while adjusting for relevant covariates. The scores were benchmarked against HIV exposed uninfected group to facilitate the interpretation. RESULTS: Seventy-one percentage of children infected with subtype A versus 60% of children with subtype D were currently on antiretroviral therapy (P = 0.49). Children with HIV-1 subtype A infection were older when compared with subtype D (3.29 vs. 2.76 years, respectively, P = 0.03), but similar regarding sex, socioeconomic status, weight-for-age z-score, CD4+ and CD8+ (% and total), viral load. No statistically significant differences by HIV-1 subtype were observed in the MSEL, COAT and Early Childhood Vigilance Test. Differences ≥ 0.33 of the SD were observed for the MSEL Composite Score, Receptive Language (MSEL) and Total Memory (COAT). CONCLUSIONS: In contrast to previously reported differences in ND outcomes of school-age children by HIV-1 subtype, ND scores among preschool children were similar for subtypes A and D, with few potential differences on language production and memory outcomes that favored subtype A. Further investigation with larger sample sizes and longitudinal follow-up is needed.
RCT Entities:
BACKGROUND:HIV is a neuropathogenic virus that may result in detrimental neurodevelopmental (ND) outcomes early in life. This is the first study to evaluate the effect of HIV-1 subtype on neurodevelopment of Ugandan preschool children. METHODS: Neurodevelopment of 87 HIV-1 infected and 221 HIV exposed uninfected Ugandan children 1.8-4.9 years of age was assessed using 4 scales of the Mullen Scales of Early Learning (MSEL), 2 scales of the Color Object Association Test (COAT), and 1 score of the Early Childhood Vigilance Test. HIV-1 subtype was defined by phylogenetic analyses. General linear models were used to relate test scores to HIV-1 subtype (A versus D) while adjusting for relevant covariates. The scores were benchmarked against HIV exposed uninfected group to facilitate the interpretation. RESULTS: Seventy-one percentage of children infected with subtype A versus 60% of children with subtype D were currently on antiretroviral therapy (P = 0.49). Children with HIV-1 subtype A infection were older when compared with subtype D (3.29 vs. 2.76 years, respectively, P = 0.03), but similar regarding sex, socioeconomic status, weight-for-age z-score, CD4+ and CD8+ (% and total), viral load. No statistically significant differences by HIV-1 subtype were observed in the MSEL, COAT and Early Childhood Vigilance Test. Differences ≥ 0.33 of the SD were observed for the MSEL Composite Score, Receptive Language (MSEL) and Total Memory (COAT). CONCLUSIONS: In contrast to previously reported differences in ND outcomes of school-age children by HIV-1 subtype, ND scores among preschool children were similar for subtypes A and D, with few potential differences on language production and memory outcomes that favored subtype A. Further investigation with larger sample sizes and longitudinal follow-up is needed.
Authors: Nicholas Blanchette; Mary Lou Smith; Susan King; Alda Fernandes-Penney; Stanley Read Journal: Dev Neuropsychol Date: 2002 Impact factor: 2.253
Authors: Carina Marquez; Jaffer Okiring; Gabriel Chamie; Theodore D Ruel; Jane Achan; Abel Kakuru; Moses R Kamya; Edwin D Charlebois; Diane V Havlir; Grant Dorsey Journal: J Trop Pediatr Date: 2014-08-21 Impact factor: 1.165
Authors: Jared M Baeten; Bhavna Chohan; Ludo Lavreys; Vrasha Chohan; R Scott McClelland; Laura Certain; Kishorchandra Mandaliya; Walter Jaoko; Julie Overbaugh Journal: J Infect Dis Date: 2007-03-02 Impact factor: 5.226
Authors: Lachlan Gray; Michael Roche; Melissa J Churchill; Jasminka Sterjovski; Anne Ellett; Pantelis Poumbourios; Shameem Sherieff; Shameem Sheffief; Bin Wang; Nitin Saksena; Damian F J Purcell; Steven Wesselingh; Anthony L Cunningham; Bruce J Brew; Dana Gabuzda; Paul R Gorry Journal: J Virol Date: 2009-03-25 Impact factor: 5.103
Authors: Pontiano Kaleebu; Immaculate L Nankya; David L Yirrell; Leigh Anne Shafer; Jacqueline Kyosiimire-Lugemwa; Daniel B Lule; Dilys Morgan; Simon Beddows; Jonathan Weber; James A G Whitworth Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: Paul Bangirana; Chandy C John; Richard Idro; Robert O Opoka; Justus Byarugaba; Anne M Jurek; Michael J Boivin Journal: PLoS One Date: 2009-11-19 Impact factor: 3.240
Authors: Pelekelo P Kabundula; Esau G Mbewe; Sylvia Mwanza-Kabaghe; Gretchen L Birbeck; Milimo Mweemba; Bo Wang; J Anitha Menon; David R Bearden; Heather R Adams Journal: AIDS Behav Date: 2022-04-21